No abstract

No abstract

No abstract

Background: Prostate cancer is the second leading cause of cancer death in men, moreover when it develops metastasis. However, PSA detection in serum as current gold standard to measure disease progressivity had wide variability leading to confounding outcomes. MicroRNA-21 has diagnostic values for cancer over period of time researched, yet results are still inconclusive. Objective: The aim of the study was to conduct recent meta-analysis to assess reliability of miRNA-21 as diagnostic biomarker especially in progressivity of prostate cancer. Methods: Published papers from PubMed, Science Direct, and Embase” as of 1 July 2021 assessing circulating miRNA-21 in progressivity of prostate cancer patients were analyzed using Comprehensive Meta-Analysis tool. Pooled sensitivity, specificity, positive and negative likelihood ratio (LR) and SROC assessed with 95 % confidence intervals were estimated using fixed-effects or random-effects models. Results: In total, we included 6 papers total of 651 samples reporting miRNA-21 capability of detecting progressive prostate cancer. The pooled sensitivity and specificity showed 0.91 (95% CI 0.88-0.94, I 2 =0%) and 0.89 (95% CI 0.85-0.92, I 2= 44.8%), respectively. Positive and negative likelihood ratio showed 7.18 (95% CI 4.31-11.96, I 2 =56%) and 0.11 (95% CI 0.07-0.16, I 2 =11.8%). SROC were assessed and got Area Under Curve around 97.4%. Conclusion: miRNA-21 could serve as biomarkers of prostate cancer progressivity since remarkable diagnostic value of circulating miRNA-21 in prostate cancer metastasis process.

and placebo (3 times daily), for 3 months. Anti-ds DNA serum levels were measured by ELISA and urine protein were measured by urine albumin creatinine ratio (UACR). Results After supplementation for 3 months, this study showed that decreased of anti-dsDNA serum levels in the supplementation group was significantly greater than in the placebo group. The decreased of UACR in the supplementation group was also significantly greater than the placebo group. Conclusions Adding curcumin on vitamin D supplementation can decrease anti-dsDNA serum levels and proteinuria greater than vitamin D supplementation plus placebo in SLE patients with hipovitamin D. Background and aims Vitamin D has important roles in the regulation of the immune system in Lupus. Seventy percent of lupus patients in Indonesia are experienced hypovitamin D. Curcumin is a natural VDR ligand and has sinergic effect with vitamin D. This study was aimed to determine the effect of adding curcumin on vitamin D supplementation on IFN-g/ IL-4 ratio and IL-17/TGF-b ratio, in SLE patients with hipovitamin D. Methods This was a randomised controlled trial, double blind study. Forty SLE patients with hypovitamin D were studied, that randomised into two groups: 20 patients (supplementation group) received vitamin D (cholecalciferol 1200 IU daily) with curcumin 20 mg (three times daily); and 20 patients (placebo group) was given vitamin D (cholecalciferol 1200 IU daily) and placebo ( 3 times daily), for 3 months. Cytokines serum levels ) were measured by ELISA. Results After supplementation for 3 months, this study showed that decreased of IFN-g/IL-4 ratio in the supplementation group was significantly greater than in the placebo group. The decreased of IL-17/TGF-b ratio in the supplementation group was also significantly greater than the placebo group. Background and aims Vitamin D has important role in the regulation of the immune system in Lupus. 71% of lupus patients in Indonesia experienced hypovitamin D. This study was aimed to determine the effect of vitamin D 258